Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3397-3402

  Heerema, Nyla A ^a   Carroll, Andrew J ^c   Devidas, Meenakshi ^d   Loh, Mignon L ^e   Borowitz, Michael J ^f   Gastier Foster, Julie M ^a,b   Larsen, Eric C ^g   Mattano, Leonard A ^h   Maloney, Kelly W ⁱ   Willman, Cheryl L ^j   Wood, Brent L ^k   Winick, Naomi J ^l   Carroll, William L ^m   Hunger, Stephen P ⁱ   Raetz, Elizabeth A ^m  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g Maine Children's Cancer Program Scarborough   (United States)

^h MICHIGAN STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF NEW MEXICO   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 21; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC RISK; HIGH RISK PATIENT; HUMAN; INTRACHROMOSOMAL AMPLIFICATION OF CHROMOSOME 21; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT RISK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; YOUNG ADULT; DISEASE FREE SURVIVAL; GENE TRANSLOCATION; GENETICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHROMOSOMES, HUMAN, PAIR 21; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84897568967     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.1308     Document Type: Article

References (21)

1. Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 30:1663-1669, 2012
2. Schultz KR, Pullen DJ, Sather HN, et al: Riskand response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 109:926-935, 2007
3. Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007
4. Aricò M, Schrappe M, Hunger SP, et al: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28:4755-4761, 2010
5. Aricò M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
6. Pui CH, Chessells JM, Camitta B, et al: Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 17:700-706, 2003
7. Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002
8. Harewood L, Robinson H, Harris R, et al: Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases. Leukemia 17:547-553, 2003
9. Attarbaschi A, Mann G, Panzer-Grümayer R, et al: Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: The Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 26:3046-3050, 2008
10. Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109:2327-2330, 2007
11. Robinson HM, Broadfield ZJ, Cheung KL, et al: Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17:2249-2250, 2003
12. Rand V, Parker H, Russell LJ, et al: Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. Blood 117:6848-6855, 2011
13. Strefford JC, van Delft FW, Robinson HM, et al: Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A 103:8167-8172, 2006
14. Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485, 2008
15. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
18. Moorman AV, Ensor HM, Richards SM, et al: Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11:429-438, 2010
19. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
20. Seibel NL, Steinherz PG, Sather HN, et al: Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
21. Robinson HM, Harrison CJ, Moorman AV, et al: Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusionbridge cycle. Genes Chromosomes Cancer 46:318-326, 2007